The new fund will focus on Israeli early-stage investors.
Israeli investment firm eHealth Ventures (eHV) has announced the establishment of a $30 million venture capital fund for med tech and digital health companies, with the aim of raising $40 million.
The fund, called ‘eHV Advanced’, will focus on Israeli early-stage companies at seed stage, with a focus on diagnostics, digital monitoring, digital treatments, home care and bio-convergence. It will also invest in companies that have graduated from Maccabi’s technological incubator, which eHV has led for the last five years.
eHV is an international partnership that includes Israeli health maintenance organisation (HMO) Maccabi Healthcare Services, and global pharma firms Amgen Ventures and Medison Ventures. Other investors include the Hadar Group, Arad Investment, Venturing, and Coast Capital Partners.
The firm is expected to announce the completion of the fund during the upcoming quarter.
WHY IT MATTERS
Israel is growing in its digital health investment. According to a report by Startup Nation, investments in companies operating in the country’s digital health sector crossed the $1 billion mark for the first time ever in the first half (H1) of 2021. Having raised a total of $1.021 billion in H1/2021, the sector more than doubled (114%) the $438 million raised in H1/2020 and already surpassed the full-year total of 2020 and 2019.
THE LARGER CONTEXT
Earlier this month eHealth Ventures announced an investment in its latest portfolio company, RespAI Medical, which is developing a home monitoring artificial intelligence (AI) platform to monitor patients with multiple respiratory and other diseases.
Other Israeli venture capital firms specialising in the digital health space include OTV, which has invested in firms including TytoCare, Lemonaid Health, Emedgene, Scopio and Donisi Health, and Peregrine Ventures, which has backed Valtech Cardio, Memic, CartiHeal, Cordio, Neovasc, Eximo and Magneto.
Meanwhile, Israeli digital self-neuromodulation therapy company GrayMatters Health this month announced a $10 million Series A funding round.
In 2021, Israeli digital health firms to receive large investments included stroke therapy technology company BrainQ which scored $40 million and Ibex Medical Analytics which raised $38 million in Series B funding.
Other Israeli firms which announced funding include digital health startup RenalSense which scored $14 million in its Series A round, chronic condition management firm Sweetch which raised $20 million, medical device company Butterfly Medical Ltd which raised $7 million in its Series B round, and behavourial therapy firm Eleos Health which landed $6 million in seed funding.
ON THE RECORD
Talor Sax, managing partner of eHealth Ventures, said: “We are proud to have earned the trust of our partners and friends at Maccabi, Amgen, Medison and others who are writing the next chapter in digital health investment with us.
“We will continue to be highly selective, choosing one out of one hundred evaluated companies. A portfolio company will receive full support including several rounds of funding, strategic connections, and access to its target markets – designed to enable aggressive commercialisation.”
